"description","rationale","instanceType","name","uuid:ID","label","id"
"The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","Study Design 1","5e6e22ae-f6a5-42eb-8f6a-023940061b15","","StudyDesign_1"
